Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SRZN vs CING: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (33.2 SELL vs 44.8 HOLD), While CING Leads 3–2 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: SRZN 2 – 3 CING (1 Tie) Matrix Metrics: SRZN 5 – 2 CING

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Cingulate Inc. (CING) on higher Unified Composite conviction (33.2/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 5–2 (led by Valuation Multiples, Growth & Scale), while CING wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus CING at $4.72 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs CING
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 121% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $4.71 · SMA50: $4.82

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 CING)

Columns: Metric · SRZN · CING
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 48.3x N/M
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +0.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $602.5M $62.5M
3. Profitability & Quality CING
Gross Margin N/A N/A
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -198.7%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$31M -$21M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $22M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.0% (5th %ile) 111.1% (16th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs CING (2)
Institutional Metric SRZN CING Criterion Row Edge
Market Capitalization
Scale
$602.5M $62.5M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin CING
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -198.7% Higher ROE SRZN
52-Week Range Position
Momentum
69% ($12–$38) 18% ($3–$12) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.28β · 66% Vol 1.07β · 121% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$21M ($22M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +17.2 pp
SRZN: +25.57% · CING: +8.37%
3M Horizon SRZN +35.02 pp
SRZN: +24.68% · CING: -10.34%
6M Horizon SRZN +9.44 pp
SRZN: +17.07% · CING: +7.63%
1Y Horizon SRZN +95.23 pp
SRZN: +130.62% · CING: +35.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs CING. Trailing 12-month operating profitability (SRZN -485.4% vs CING 0.0%) and valuation multiples (SRZN N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M
CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs CING Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Cingulate Inc. (CING) on higher Unified Composite conviction (33.2/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 5–2 (led by Valuation Multiples, Growth & Scale), while CING wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus CING at $4.72 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY). Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with CING at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRZN generates $11M in USD-normalized revenue versus N/A for CING. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CING.

SRZN screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus CING (-198.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk). By comparison, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.07β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.